Although these studies provide some indication that anti-inflammatory strategies targeting the MCP-1/CCL2 or the JAK–STAT pathway may be a fruitful approach to delay the progression of diabetic kidney disease, many questions remain unanswered. This evidence concerns the gene CCL2 and diabetic kidney disease.